(Q26782607)

1

0 references

Robert Centor

2

0 references

Raquel C Greer

4

0 references

Michael Choi

5

0 references

Thomas D Sequist

American Journal of Medicine

6

0 references

language of work or name

English

0 references

publication date

February 2016

0 references

published in

0 references

volume

129

0 references

page(s)

153-162.e7

0 references

issue

2

0 references

cites work

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The usefulness of diagnostic testing in the initial evaluation of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Primary care management of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Acute kidney injury after CABG versus PCI: an observational study using 2 cohorts

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Reporting of estimated GFR in the primary care clinic

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Managing older adults with CKD: individualized versus disease-based approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Renal syndromes associated with nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Combined angiotensin inhibition for the treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Acetaminophen, aspirin and progression of advanced chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Predialysis nephrologist care and access to kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Early predictors of 15-year end-stage renal disease in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Bicarbonate supplementation slows progression of CKD and improves nutritional status

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

A randomized trial of dietary sodium restriction in CKD

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Use of metformin in the setting of mild-to-moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

The timing of specialist evaluation in chronic kidney disease and mortality

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021

Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2015.08.025

7 January 2021